# Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01289990` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01289990](<https://clinicaltrials.gov/study/NCT01289990>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01289990

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2705 participants.

## Technical summary

Registry record NCT01289990. Non-randomized; double masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2014-07-15.

## Key facts

- Design: Interventional study; non-randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2705 participants (enrolled count; ClinicalTrials.gov record NCT01289990, source copy `cardio:ctgov-nct01289990-2014-07-15`, retrieved 2026-10-26)
- Start date: 2011-02 (registry gives no type) (ClinicalTrials.gov record NCT01289990, source copy `cardio:ctgov-nct01289990-2014-07-15`, retrieved 2026-10-26)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01289990, source copy `cardio:ctgov-nct01289990-2014-07-15`, retrieved 2026-10-26)
- Completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01289990, source copy `cardio:ctgov-nct01289990-2014-07-15`, retrieved 2026-10-26)
- Results first posted: 2014-07-15 (ClinicalTrials.gov record NCT01289990, source copy `cardio:ctgov-nct01289990-2014-07-15`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; China; France; Germany; Greece; India; Ireland; Japan; Mexico; Philippines; Slovakia; Slovenia; South Korea; Switzerland; Taiwan; Türkiye; Ukraine (ClinicalTrials.gov record NCT01289990, source copy `cardio:ctgov-nct01289990-2014-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01289990-2014-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): BI 10773
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): BI 10773
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): BI 10773
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): BI 10773
- Intervention (Drug): BI 10773
- Intervention (Drug): BI 10773
- Intervention (Drug): Placebo
- Intervention (Drug): BI 10773
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Sitagliptin 100mg
- Intervention (Drug): BI 10773
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes (`cardio:pubmed-26324220`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial (`cardio:pubmed-26701110`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 589403619b97328d36ae41a4474712d4529bfe59c87feb9f74354bdcdaa91946
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
